Daiwa Securities Group Inc. Acquires 2,234 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Daiwa Securities Group Inc. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 20,384 shares of the biopharmaceutical company's stock after buying an additional 2,234 shares during the period. Daiwa Securities Group Inc.'s holdings in Regeneron Pharmaceuticals were worth $21,428,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in REGN. Sachetta LLC grew its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 10 shares during the period. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $26,000. Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $33,000. Finally, Family Firm Inc. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at $33,000. Institutional investors own 83.31% of the company's stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.48% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Leerink Partners reissued a "market perform" rating and issued a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Finally, Royal Bank of Canada dropped their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $1,099.55.

Regeneron Pharmaceuticals Trading Up 1.6 %

REGN traded up $11.51 on Monday, hitting $749.51. The company had a trading volume of 1,196,249 shares, compared to its average volume of 542,203. Regeneron Pharmaceuticals, Inc. has a 12-month low of $735.95 and a 12-month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The business's fifty day simple moving average is $937.00 and its 200 day simple moving average is $1,025.99. The company has a market cap of $82.36 billion, a PE ratio of 18.55, a PEG ratio of 2.84 and a beta of 0.15.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.